Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS.

Zhu S, Wuolikainen A, Wu J, Öhman A, Wingsle G, Moritz T, Andersen PM, Forsgren L, Trupp M.

J Mol Neurosci. 2019 Dec;69(4):643-657. doi: 10.1007/s12031-019-01411-y. Epub 2019 Nov 12.

2.

Activities of daily living in Parkinson's disease: Time/gender perspective.

Sperens M, Georgiev D, Eriksson Domellöf M, Forsgren L, Hamberg K, Hariz GM.

Acta Neurol Scand. 2020 Feb;141(2):168-176. doi: 10.1111/ane.13189. Epub 2019 Nov 20.

PMID:
31693751
3.

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O, Odin P, Widner H, Brolin K, Mzezewa R, Kristensen J, Soller M, Rödström EY, Ross OA, Toft M, Breedveld GJ, Bonifati V, Brodin L, Zettergren A, Sydow O, Linder J, Wirdefeldt K, Svenningsson P, Nissbrandt H, Belin AC, Forsgren L, Swanberg M.

Parkinsonism Relat Disord. 2019 Sep;66:158-165. doi: 10.1016/j.parkreldis.2019.07.032. Epub 2019 Jul 31.

4.

Author response: Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study.

Bäckström D, Domellöf ME, Forsgren L.

Neurology. 2019 Aug 6;93(6):279. doi: 10.1212/WNL.0000000000007908. No abstract available.

PMID:
31383808
5.

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.

Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235. doi: 10.1073/pnas.1821409116. Epub 2019 Jul 3.

6.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
7.

Combinatory microRNA serum signatures as classifiers of Parkinson's disease.

Patil KS, Basak I, Dalen I, Hoedt E, Lange J, Lunde KA, Liu Y, Tysnes OB, Forsgren L, Aarsland D, Neubert TA, Larsen JP, Alves G, Møller SG.

Parkinsonism Relat Disord. 2019 Jul;64:202-210. doi: 10.1016/j.parkreldis.2019.04.010. Epub 2019 Apr 11.

PMID:
31003905
8.

General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study.

Riso L, Kaaks R, Kühn T, Sookthai D, Forsgren L, Trupp M, Trichopoulou A, La Vecchia C, Karakatsani A, Gavrila D, Ferrari P, Freisling H, Petersson J, Lewan S, Vermeulen RC, Panico S, Masala G, Ardanaz E, Krogh V, Perneczky R, Middleton LT, Mokoroa O, Sacerdote C, Sieri S, Hayat SA, Brayne C, Riboli E, Vineis P, Gallo V, Katzke VA.

Parkinsonism Relat Disord. 2019 May;62:98-104. doi: 10.1016/j.parkreldis.2019.01.019. Epub 2019 Feb 8.

PMID:
30772279
9.

Exploring causality of the association between smoking and Parkinson's disease.

Gallo V, Vineis P, Cancellieri M, Chiodini P, Barker RA, Brayne C, Pearce N, Vermeulen R, Panico S, Bueno-de-Mesquita B, Vanacore N, Forsgren L, Ramat S, Ardanaz E, Arriola L, Peterson J, Hansson O, Gavrila D, Sacerdote C, Sieri S, Kühn T, Katzke VA, van der Schouw YT, Kyrozis A, Masala G, Mattiello A, Perneczky R, Middleton L, Saracci R, Riboli E.

Int J Epidemiol. 2019 Jun 1;48(3):912-925. doi: 10.1093/ije/dyy230.

10.

Balance and mobility in patients with newly diagnosed Parkinson's disease - a five-year follow-up of a cohort in northern Sweden.

Johansson C, Lindström B, Forsgren L, Johansson GM.

Disabil Rehabil. 2018 Nov 19:1-10. doi: 10.1080/09638288.2018.1509240. [Epub ahead of print]

PMID:
30451551
11.

Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study.

Bäckström D, Granåsen G, Domellöf ME, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L.

Neurology. 2018 Nov 27;91(22):e2045-e2056. doi: 10.1212/WNL.0000000000006576. Epub 2018 Oct 31.

12.

Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease.

Lunde KA, Chung J, Dalen I, Pedersen KF, Linder J, Domellöf ME, Elgh E, Macleod AD, Tzoulis C, Larsen JP, Tysnes OB, Forsgren L, Counsell CE, Alves G, Maple-Grødem J.

Alzheimers Dement. 2018 Oct;14(10):1293-1301. doi: 10.1016/j.jalz.2018.04.006. Epub 2018 May 21.

PMID:
29792872
13.

[Epilepsy: incidens, prevalens and causes].

Forsgren L, Sundelin H, Sveinsson O.

Lakartidningen. 2018 May 21;115. pii: E6FD. Swedish.

14.

Deep brain stimulation in the caudal zona incerta versus best medical treatment in patients with Parkinson's disease: a randomised blinded evaluation.

Blomstedt P, Stenmark Persson R, Hariz GM, Linder J, Fredricks A, Häggström B, Philipsson J, Forsgren L, Hariz M.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):710-716. doi: 10.1136/jnnp-2017-317219. Epub 2018 Jan 31.

15.

PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study.

Bäckström D, Domellöf ME, Granåsen G, Linder J, Mayans S, Elgh E, Mo SJ, Forsgren L.

J Neurol Sci. 2017 Oct 15;381:278-284. doi: 10.1016/j.jns.2017.08.3259. Epub 2017 Sep 1.

PMID:
28991698
16.

Polymorphisms in dopamine-associated genes and cognitive decline in Parkinson's disease.

Bäckström D, Eriksson Domellöf M, Granåsen G, Linder J, Mayans S, Elgh E, Zetterberg H, Blennow K, Forsgren L.

Acta Neurol Scand. 2018 Jan;137(1):91-98. doi: 10.1111/ane.12812. Epub 2017 Sep 4.

17.

The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal.

Berge-Seidl V, Pihlstrøm L, Maple-Grødem J, Forsgren L, Linder J, Larsen JP, Tysnes OB, Toft M.

Neurosci Lett. 2017 Sep 29;658:48-52. doi: 10.1016/j.neulet.2017.08.040. Epub 2017 Aug 19.

PMID:
28830825
18.

How long for epilepsy remission in the ILAE definition?

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S.

Epilepsia. 2017 Aug;58(8):1486-1487. doi: 10.1111/epi.13821. No abstract available.

19.

Gender differences in Parkinson's disease: A clinical perspective.

Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM.

Acta Neurol Scand. 2017 Dec;136(6):570-584. doi: 10.1111/ane.12796. Epub 2017 Jul 2. Review.

PMID:
28670681
20.

Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.

Horvath I, Iashchishyn IA, Forsgren L, Morozova-Roche LA.

ACS Chem Neurosci. 2017 Jun 21;8(6):1170-1176. doi: 10.1021/acschemneuro.7b00063. Epub 2017 Mar 10.

PMID:
28263550
21.

Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease.

Domellöf ME, Lundin KF, Edström M, Forsgren L.

Parkinsonism Relat Disord. 2017 May;38:41-47. doi: 10.1016/j.parkreldis.2017.02.017. Epub 2017 Feb 21.

PMID:
28242255
22.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K; Swedish BioFINDER study.

Neurology. 2017 Mar 7;88(10):930-937. doi: 10.1212/WNL.0000000000003680. Epub 2017 Feb 8.

23.

Fractional Anisotropy and Mean Diffusion as Measures of Dopaminergic Function in Parkinson's Disease: Challenging Results.

Lenfeldt N, Eriksson J, Åström B, Forsgren L, Mo SJ.

J Parkinsons Dis. 2017;7(1):129-142. doi: 10.3233/JPD-161011.

PMID:
28106567
24.

Moist smokeless tobacco (Snus) use and risk of Parkinson's disease.

Yang F, Pedersen NL, Ye W, Liu Z, Norberg M, Forsgren L, Trolle Lagerros Y, Bellocco R, Alfredsson L, Knutsson A, Jansson JH, Wennberg P, Galanti MR, Lager ACJ, Araghi M, Lundberg M, Magnusson C, Wirdefeldt K.

Int J Epidemiol. 2017 Jun 1;46(3):872-880. doi: 10.1093/ije/dyw294.

PMID:
27940486
25.

Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.

Machaczka M, Paucar M, Björkvall CK, Smith NJC, Cox TM, Forsgren L, Svenningsson P.

Blood Cells Mol Dis. 2018 Feb;68:86-92. doi: 10.1016/j.bcmd.2016.10.011. Epub 2016 Oct 21.

PMID:
27789132
26.

Intake of vitamin B before onset of Parkinson's disease and atypical parkinsonism and olfactory function at the time of diagnosis.

Håglin L, Johansson I, Forsgren L, Bäckman L.

Eur J Clin Nutr. 2017 Jan;71(1):97-102. doi: 10.1038/ejcn.2016.181. Epub 2016 Oct 5.

PMID:
27703161
27.

Frontal white matter injuries predestine gait difficulties in Parkinson's disease.

Lenfeldt N, Holmlund H, Larsson A, Birgander R, Forsgren L.

Acta Neurol Scand. 2016 Sep;134(3):210-8. doi: 10.1111/ane.12532. Epub 2015 Nov 17.

PMID:
27465659
28.

Rare variants in dementia genes and Parkinson's disease.

Iqbal Z, Pihlstrøm L, Rengmark A, Henriksen SP, Linder J, Forsgren L, Toft M.

Eur J Hum Genet. 2016 Dec;24(12):1661-1662. doi: 10.1038/ejhg.2016.79. Epub 2016 Jun 22. No abstract available.

29.

Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.

Ran C, Brodin L, Forsgren L, Westerlund M, Ramezani M, Gellhaar S, Xiang F, Fardell C, Nissbrandt H, Söderkvist P, Puschmann A, Ygland E, Olson L, Willows T, Johansson A, Sydow O, Wirdefeldt K, Galter D, Svenningsson P, Belin AC.

Neurobiol Aging. 2016 Sep;45:212.e5-212.e11. doi: 10.1016/j.neurobiolaging.2016.04.022. Epub 2016 May 3.

30.

Low frequency of GCH1 and TH mutations in Parkinson's disease.

Rengmark A, Pihlstrøm L, Linder J, Forsgren L, Toft M.

Parkinsonism Relat Disord. 2016 Aug;29:109-11. doi: 10.1016/j.parkreldis.2016.05.010. Epub 2016 May 7.

PMID:
27185167
31.

Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects.

Wuolikainen A, Jonsson P, Ahnlund M, Antti H, Marklund SL, Moritz T, Forsgren L, Andersen PM, Trupp M.

Mol Biosyst. 2016 Apr;12(4):1287-98. doi: 10.1039/c5mb00711a. Epub 2016 Feb 17.

PMID:
26883206
32.

Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes.

Valadas A, Contarino MF, Albanese A, Bhatia KP, Falup-Pecurariu C, Forsgren L, Friedman A, Giladi N, Hutchinson M, Kostic VS, Krauss JK, Lokkegaard A, Marti MJ, Milanov I, Pirtosek Z, Relja M, Skorvanek M, Stamelou M, Stepens A, Tamás G, Taravari A, Tzoulis C, Vandenberghe W, Vidailhet M, Ferreira JJ, Tijssen MA.

Eur J Neurol. 2016 Apr;23(4):772-9. doi: 10.1111/ene.12940. Epub 2016 Jan 29.

PMID:
26826067
33.

Long-term dopamine transporter imaging in Parkinson's disease treated with zona incerta stimulation.

Mo SJ, Linder J, Blomstedt P, Granåsen G, Forsgren L, Hariz M.

Nucl Med Commun. 2016 May;37(5):499-508. doi: 10.1097/MNM.0000000000000469.

PMID:
26716545
34.

Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease.

Horvath I, Jia X, Johansson P, Wang C, Moskalenko R, Steinau A, Forsgren L, Wågberg T, Svensson J, Zetterberg H, Morozova-Roche LA.

ACS Chem Neurosci. 2016 Jan 20;7(1):34-9. doi: 10.1021/acschemneuro.5b00265. Epub 2015 Nov 12.

PMID:
26550994
35.

Olfactory Function, Eating Ability, and Visceral Obesity Associated with MMSE Three Years after Parkinson's Disease Diagnosis.

Vikdahl M, Domellöf ME, Forsgren L, Håglin L.

J Nutr Health Aging. 2015 Nov;19(9):894-900. doi: 10.1007/s12603-015-0573-1.

PMID:
26482690
36.

Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study.

Gallo V, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S, Mattiello A, Kaaks R, Teucher B, Katzke V, Kloss M, Curry L, Calboli F, Riboli E, Vineis P, Middleton L.

Neurodegener Dis. 2015;15(6):331-8. doi: 10.1159/000381857. Epub 2015 Sep 17.

PMID:
26375921
37.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.

JAMA Neurol. 2015 Oct;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

PMID:
26258692
38.

Fractional anisotropy in the substantia nigra in Parkinson's disease: a complex picture.

Lenfeldt N, Larsson A, Nyberg L, Birgander R, Forsgren L.

Eur J Neurol. 2015 Oct;22(10):1408-14. doi: 10.1111/ene.12760. Epub 2015 Jun 29.

PMID:
26118635
39.

Oral Appliance Therapy in Patients With Daytime Sleepiness and Snoring or Mild to Moderate Sleep Apnea: A Randomized Clinical Trial.

Marklund M, Carlberg B, Forsgren L, Olsson T, Stenlund H, Franklin KA.

JAMA Intern Med. 2015 Aug;175(8):1278-85. doi: 10.1001/jamainternmed.2015.2051.

PMID:
26030264
40.

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.

Lill CM, Rengmark A, Pihlstrøm L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, Meissner E, Alexopoulos P, Calvo A, Chio A, Dizdar N, Faltraco F, Forsgren L, Kirchheiner J, Kurz A, Larsen JP, Liebsch M, Linder J, Morrison KE, Nissbrandt H, Otto M, Pahnke J, Partch A, Restagno G, Rujescu D, Schnack C, Shaw CE, Shaw PJ, Tumani H, Tysnes OB, Valladares O, Silani V, van den Berg LH, van Rheenen W, Veldink JH, Lindenberger U, Steinhagen-Thiessen E; SLAGEN Consortium, Teipel S, Perneczky R, Hakonarson H, Hampel H, von Arnim CAF, Olsen JH, Van Deerlin VM, Al-Chalabi A, Toft M, Ritz B, Bertram L.

Alzheimers Dement. 2015 Dec;11(12):1407-1416. doi: 10.1016/j.jalz.2014.12.009. Epub 2015 Apr 30.

41.

Fine mapping and resequencing of the PARK16 locus in Parkinson's disease.

Pihlstrøm L, Rengmark A, Bjørnarå KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Dietrichs E, Toft M.

J Hum Genet. 2015 Jul;60(7):357-62. doi: 10.1038/jhg.2015.34. Epub 2015 Apr 9.

PMID:
25855069
42.

NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson's disease and controls.

Öhman A, Forsgren L.

Neurosci Lett. 2015 May 6;594:36-9. doi: 10.1016/j.neulet.2015.03.051. Epub 2015 Mar 27.

PMID:
25817365
43.

Cognitive function in the early phase of Parkinson's disease, a five-year follow-up.

Domellöf ME, Ekman U, Forsgren L, Elgh E.

Acta Neurol Scand. 2015 Aug;132(2):79-88. doi: 10.1111/ane.12375. Epub 2015 Feb 3.

PMID:
25644230
44.

Cardiovascular risk factors and the risk of Parkinson's disease.

Vikdahl M, Bäckman L, Johansson I, Forsgren L, Håglin L.

Eur J Clin Nutr. 2015 Jun;69(6):729-33. doi: 10.1038/ejcn.2014.259. Epub 2014 Dec 17.

PMID:
25514902
45.

Long leukocyte telomere length at diagnosis is a risk factor for dementia progression in idiopathic parkinsonism.

Degerman S, Domellöf M, Landfors M, Linder J, Lundin M, Haraldsson S, Elgh E, Roos G, Forsgren L.

PLoS One. 2014 Dec 12;9(12):e113387. doi: 10.1371/journal.pone.0113387. eCollection 2014.

46.

Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism.

Jakobson Mo S, Linder J, Forsgren L, Riklund K.

Mov Disord Clin Pract. 2014 Sep 30;2(1):17-23. doi: 10.1002/mdc3.12089. eCollection 2015 Mar.

47.

Longitudinal changes in task-evoked brain responses in Parkinson's disease patients with and without mild cognitive impairment.

Ekman U, Eriksson J, Forsgren L, Domellöf ME, Elgh E, Lundquist A, Nyberg L.

Front Neurosci. 2014 Jul 29;8:207. doi: 10.3389/fnins.2014.00207. eCollection 2014.

48.

Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.

Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, Wuolikainen A, Linder J, Moritz T, Blennow K, Antti H, Forsgren L.

J Parkinsons Dis. 2014;4(3):549-60. doi: 10.3233/JPD-140389.

PMID:
24927756
49.

ILAE official report: a practical clinical definition of epilepsy.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S.

Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14. Review.

50.

A generic method for design of oligomer-specific antibodies.

Brännström K, Lindhagen-Persson M, Gharibyan AL, Iakovleva I, Vestling M, Sellin ME, Brännström T, Morozova-Roche L, Forsgren L, Olofsson A.

PLoS One. 2014 Mar 11;9(3):e90857. doi: 10.1371/journal.pone.0090857. eCollection 2014.

Supplemental Content

Loading ...
Support Center